Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa

Andrew N. Phillips; John Stover; Valentina Cambiano; Fumiyo Nakagawa; Michael R. Jordan; Deenan Pillay; Meg Doherty; Paul Revill; Silvia Bertagnolio

doi:10.1093/infdis/jix089

Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa

Andrew N. Phillips, John Stover, Valentina Cambiano, Fumiyo Nakagawa, Michael R. Jordan, Deenan Pillay, Meg Doherty, Paul Revill, Silvia Bertagnolio

School of Medicine

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub- Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be attributable to HIVDR.

Original language	English (US)
Pages (from-to)	1362-1365
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	215
Issue number	9
DOIs	https://doi.org/10.1093/infdis/jix089
State	Published - May 1 2017

Keywords

HIV
cost
death
drug resistance
incidence
mathematical model

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/jix089

Cite this

@article{4ddfe5efa1a644fa8f66b38ef5002a8a,

title = "Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa",

abstract = "To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub- Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be attributable to HIVDR.",

keywords = "HIV, cost, death, drug resistance, incidence, mathematical model",

author = "Phillips, {Andrew N.} and John Stover and Valentina Cambiano and Fumiyo Nakagawa and Jordan, {Michael R.} and Deenan Pillay and Meg Doherty and Paul Revill and Silvia Bertagnolio",

note = "Publisher Copyright: {\textcopyright} The Author 2017. Published by Oxford University Press for the Infectious Diseases Society.",

year = "2017",

month = may,

day = "1",

doi = "10.1093/infdis/jix089",

language = "English (US)",

volume = "215",

pages = "1362--1365",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa

AU - Phillips, Andrew N.

AU - Stover, John

AU - Cambiano, Valentina

AU - Nakagawa, Fumiyo

AU - Jordan, Michael R.

AU - Pillay, Deenan

AU - Doherty, Meg

AU - Revill, Paul

AU - Bertagnolio, Silvia

N1 - Publisher Copyright: © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub- Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be attributable to HIVDR.

AB - To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub- Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be attributable to HIVDR.

KW - HIV

KW - cost

KW - death

KW - drug resistance

KW - incidence

KW - mathematical model

UR - http://www.scopus.com/inward/record.url?scp=85022002176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022002176&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix089

DO - 10.1093/infdis/jix089

M3 - Article

C2 - 28329236

AN - SCOPUS:85022002176

SN - 0022-1899

VL - 215

SP - 1362

EP - 1365

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 9

ER -

Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this